Mission Barns Revamps Single-Cell Suspension Pharma Bioreactors to Scale Cultivated Meat Production

Mission Barns has developed a new bioreactor to optimize cultivated meat production, aiming to replace traditional single-cell suspension bioreactors from the pharmaceutical industry. Their technology platform starts from non-GMO adherent cells and grows them using an animal-free cell culture medium to produce products like cultivated pork fat. The redesigned bioreactor provides efficient cell growth and harvesting, supports multiple species, uses less space, and can produce whole-cut products in a single vessel.

By scaling up their bioreactor to over 500 times its original size and completing over 100 successful runs in their pilot facility, Mission Barns aims to demonstrate large-scale production and reach price parity with traditional pork products. With a dual B2C and B2B business model, the company plans to create a consumer-facing brand and partner with grocery stores, restaurants, and food distributors, while also licensing technology to large food companies or co-developing co-branded products for the industry.